Callan Family Office’s Boston Scientific BSX Stock Holding History

Callan Family Office’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25M	Buy	52,745 +21,471	+69%	+$1.17M	0.04%	356
2026 Q1	$1.96M	Sell	31,274 -23,752	-43%	-$1.9M	0.04%	362
2025 Q4	$5.25M	Buy	55,026 +22,519	+69%	+$2.21M	0.11%	184
2025 Q3	$3.17M	Buy	32,507 +4,110	+14%	+$426K	0.1%	208
2025 Q2	$3.05M	Buy	28,397 +21,203	+295%	+$2.15M	0.1%	218
2025 Q1	$726K	Sell	7,194 -1,404	-16%	-$141K	0.05%	255
2024 Q4	$768K	Buy	+8,598	New	+$757K	0.05%	293

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Callan Family Office's BSX Position: Q2 2026 in Review

Callan Family Office increased its Boston Scientific (BSX) stake by 69% in Q2 2026, buying an estimated $1.17M and bringing the position to 52,745 shares worth $2.25M. The position accounts for 0.04% of the portfolio, ranked #356.

Callan Family Office first reported a position in BSX in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.25M in Q4 2025. 1,487 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Callan Family Office held 52,745 shares of Boston Scientific worth $2.25M as of Q2 2026.
Callan Family Office bought 21,471 Boston Scientific shares in Q2 2026, an estimated $1.17M.
Boston Scientific made up 0.04% of Callan Family Office's portfolio in Q2 2026, its #356 holding.
Callan Family Office first reported a position in Boston Scientific in Q4 2024 and has held it in 7 quarters since.
Callan Family Office's Boston Scientific position peaked at $5.25M in Q4 2025.
1,487 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.